Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bausch health
biotech
clinical trials
dihydroergotamine
2
×
glaxosmithkline
life sciences
migraine
multiple myeloma
national blog main
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
satsuma pharmaceuticals
abbvie
acute migrane
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
alzheimer's disease
antibiotics
axial spondyloarthritis
bain capital
biogen
boston blog main
boston top stories
boston university
boulder/denver blog main
boulder/denver top stories
breast cancer
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
cluster headache
What
companies
drug
2
×
activity
approval
bio
biogen’s
biopharmaceutical
biotech
convo
days
dog
earlier
failures
firm
hasn’t
ipo
ipos
leading
line
littered
migraine
nash
new
news
pfizer
place
prep
price
remains
road
roundup
satsuma
securing
slowed
spinout
springworks
stopped
strategy
summer
talk
Language
unset
Current search:
dihydroergotamine
×
drug
×
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
